Best of ESMO 2024 On Demand in Japan

解説【LBA28】ENGOT-en11/GOG-3053/KEYNOTE-B21: A Phase 3 Study of Pembrolizumab or Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Patients With Newly Diagnosed, High-Risk Endometrial Cancer

Best of ESMO 2024 On Demand in Japan

解説【LBA28】ENGOT-en11/GOG-3053/KEYNOTE-B21: A Phase 3 Study of Pembrolizumab or Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Patients With Newly Diagnosed, High-Risk Endometrial Cancer

この動画に関するお問い合わせ先

Best of ESMO 2024運営事務局 

株式会社サンプラネット 東京事業部

E-mail:jsmo-seminar@sunpla-mcv.com

 

西川 忠曉 Nishikawa Tadaaki

東京慈恵会医科大学 産婦人科学講座

0.14945602416992 秒